ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KLRA / news
NUVB (19) ANIP (63) STOK (46) QURE (38) ⌘ Pro Terminal →

Why KLRA Stock dropped -5.52% Today — RQD Quant Desk Flash

$12.15 -5.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.01

Kailera Therapeutics Inc. (KLRA) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.67B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KLRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KLRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kailera Therapeutics Inc. (NASDAQ: KLRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $12.15 (-5.52% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KLRA ranks #361 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KLRA compare to NUVB and ANIP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KLRA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NUVB (Nuvation Bio Inc. (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and ANIP (ANI Pharmaceuticals Inc.) posts a C grade (63/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.65B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KLRA?
▼

Per KLRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002096997), Kailera Therapeutics Inc. generated $290.8M in revenue, $0 in net income, and $0 in free cash flow against $692.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.01 (-1.18%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 16.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (10)Whales (6)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$30 Bull$11 Base$9 Bear
📬 FREE KLRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KLRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY KLRA SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 16.1% FCF Margin ($46.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$10.77+19.7% Next Q
Q2 (-2Q)
40
Grade D$12.89+1.9% Next Q
Q3 (-1Q)
42
Grade D$13.13-7.5% Next Q
Current
45
Grade D$12.15-6.3% Hist 90D α
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KLRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KLRA currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.14) and Max Pain ($12.76) forces dealer call-delta covering toward $29.64.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KLRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KLRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why KLRA Stock dropped -5.52% Today — RQD Quant Desk Flash

Kailera Therapeutics Inc. (KLRA) dropped -5.52% to $12.15, trading at 13% of its 52-week range ($9.76 – $28.23). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 13% of its 52-week range ($9.76 – $28.23) with RSI-14 at 51.7 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $12.15 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $46.7M annual free cash flow.
Live KLRA Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KLRA)

  • ✓Walkthrough of KLRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KLRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.57%⚡ TESTING RESISTANCE
2026-11-03O $13.41H $13.41L $12.15C $12.15VOL 868.4K
RES: $13.46SUP: $8.06SMA50: $13.14SMA200: $17.91
$26.82$22.19$17.57$12.95$8.33RES $13.46SUP $8.06$12.152026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KLRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KLRA Butterfly Map → + Track KLRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KLRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KLRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KLRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KLRA)

Health Care Rank #361 of 1015 ⚔️ NUVB vs KLRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KLRA vs. NUVB, ANIP, STOK, QURE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kailera Therapeutics Inc. (KLRA) ranks #361 by composite RQD confidence (45/100, grade D) and #284 by equity capitalization ($1.67B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with KLRA at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KLRA ACTIVE
Kailera Therapeutics Inc.
D 45/100 — — — -5.52% $1.67B Benchmark Subject
NUVB
Nuvation Bio Inc. (Class A)
E 19/100 — — -35.0% -3.57% $1.67B /nuvb-vs-klra →
ANIP
ANI Pharmaceuticals Inc.
C 63/100 21.5x — 16.0% -1.85% $1.65B /anip-vs-klra →
STOK
Stoke Therapeutics Inc.
D 46/100 — — -6.1% +0.72% $1.70B /stok-vs-klra →
QURE
uniQure N.V.
D- 38/100 — — -35.0% -7.49% $1.72B /qure-vs-klra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002096997 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kailera Therapeutics Inc. (KLRA) reported GAAP revenue of $290.8M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KLRA closed FY2025 with $692.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $290.8M $0 — — $692.3M —

3. KLRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KLRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kailera Therapeutics Inc. (NASDAQ: KLRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $12.15 (-5.52% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KLRA ranks #361 in composite RQD confidence.

How does KLRA compare to NUVB and ANIP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KLRA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NUVB (Nuvation Bio Inc. (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and ANIP (ANI Pharmaceuticals Inc.) posts a C grade (63/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.65B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KLRA?

Per KLRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002096997), Kailera Therapeutics Inc. generated $290.8M in revenue, $0 in net income, and $0 in free cash flow against $692.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KLRA trading relative to its 50-day, 200-day, and 52-week technical levels?

KLRA last traded at $12.15 (-5.52% on volume of 881,438 shares), positioning the stock -7.53% below its 50-day simple moving average ($13.14) and -32.16% below its 200-day simple moving average ($17.91). Across its 52-week range of $9.76 to $28.23, KLRA sits at the 12.9% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.63 to $13.67).

Direct Sub-Reports: KLRA RQD Cockpit KLRA 12M Forecast KLRA Earnings & Move KLRA Dividends & DRIP KLRA Insiders & 13F KLRA Whale Options KLRA Profit Sankey KLRA News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

KLRA — Kailera Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kailera Therapeutics Inc. (KLRA) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $12.15 (-5.52% 1D, market capitalization $1.67B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kailera Therapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile describes it as an issuer operating in this industry with a market capitalization of $1.7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kailera Therapeutics Inc. (KLRA) reported $290.8M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $692.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $9.76 – $28.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only cross-reference a prospective investor can draw is the October 14 lock-up expiry noted above, which is a timing item rather than a supply-chain dependency.

  • Key Question #1: Can KLRA sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $290.8M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KLRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KLRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kailera Therapeutics Inc. (KLRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KLRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KLRA Bull vs. Bear Conversation Board — What's Your Call at $12.15?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KLRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KLRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $15.43 (+20.0%)
📌 Pinned Debate

Forensic balance sheet pillar scores 13/20 with an Altman Z of 2.5, a Piotroski F of 6/9, and cash of $160.3M.

Long KLRA at $12.86 targeting $15.43. Forensic balance sheet pillar scores 13/20 with an Altman Z of 2.5, a Piotroski F of 6/9, and cash of $160.3M.. Institutional whale score is 6/20 and the risk/reward vs. the $9.76 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — KLRA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $10.03 (-22.0%)
Spot @ $12.86

Zero reported revenue, zero ROIC and zero FCF yield against a $1.74B market cap leaves the valuation with no earnings support.

Sitting on the sidelines or leaning short KLRA above $12.86. Zero reported revenue, zero ROIC and zero FCF yield against a $1.74B market cap leaves the valuation with no earnings support.. Until Fundamental Cash Engine (10/20) and FCF yield (0.0%) inflect higher, upside is capped near $28.23.

LIVE TAPE